ImmuPharma plc (LON:IMM – Get Free Report) traded up 9.7% during trading on Friday . The company traded as high as GBX 4.50 ($0.06) and last traded at GBX 3.95 ($0.05). 24,599,076 shares changed hands during mid-day trading, an increase of 28% from the average session volume of 19,273,818 shares. The stock had previously closed at GBX 3.60 ($0.04).
ImmuPharma Trading Up 13.7 %
The business has a 50 day moving average of GBX 1.71 and a 200-day moving average of GBX 1.72. The stock has a market cap of £17.04 million, a PE ratio of -409.20 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- Why Invest in 5G? How to Invest in 5G Stocks
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Top Biotech Stocks: Exploring Innovation Opportunities
- 3 Buy-and-Hold Stocks for Long-Term Growth
- What is Insider Trading? What You Can Learn from Insider Trading
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
